TP53 and acute myeloid leukemia: Although MDM2i require wt-p53 to be effective, hence being unable to act directly in TP53mut AML, they indirectly induce degradation of MCL-1, which is associated with VEN resistance, thus providing a rationale for the combined use of MDM2i and VEN, even in TP53mut patients, in order to overcome VEN resistance [104].